ABL-directed tyrosine kinase inhibitors (TKIs) such as imatinib and second-generation TKIs have proven to be effective against BCR::ABL1, achieving deep long-term remission in most chronic phase (CP) CML patients [1]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.